Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q2- Text added to 2020 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
AB, added, adjusted, applied, automatically, BioInvent, blocking, checkpoint, comprised, contractual, converted, convertible, conveyed, derecognized, description, director, disbursed, discovery, Electronic, factory, fourth, fully, guard, house, immunity, immunotherapy, inhibitory, installation, instrument, issuer, Keytruda, lead, MabThera, mainland, modification, monthly, narrative, ordinary, pembrolizumab, percentage, preference, prospectively, range, rational, receptor, removed, retain, rituximab, round, SEK, slight, solid, space, stake, structured, subscribe, subscription, substantive, Supplementary, tiered, tranche, unlock, unobservable, vendor, volume, waived, warehouse, warrant
Removed:
considerably, domestic, evaluating, free, niche, relapsed, transitional
Valuein 2020 Q2 filing- Value in 2020 Q3 filing
Original filings
Filing view